LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--April 19, 2005--BioSante Pharmaceuticals, Inc. (Amex:BPA) today announced the presentation of new data from a study of BioVant(TM), the company’s patented calcium phosphate (CaP) nanoparticle technology at the annual World Vaccine Congress in Montreal. Dr. Steve Bell, vice president of research and pre-clinical development for BioSante, will present a case study entitled, “Using Calcium Phosphate Particles for Safe Non-injection Delivery and Immune Enhancement of Biodefense and Other Vaccines” today at 2:45 p.m. ET. The main focus of Dr. Bell’s presentation is the intranasal mucosal surface delivery of an anthrax vaccine, and highlights the simultaneous immune enhancement (i.e. immune adjuvant) effects and non-injected vaccine delivery potential of CaP. The anthrax vaccine is being developed under a subcontract with DynPort Vaccine Company for the U.S. Department of Defense.
